Patent ID: 8193177

Claim:
A method for treating a fibrotic connective tissue disease or disorder comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising a carrier and a compound of formula (I): and tautomers thereof; wherein B is a C(3)- or C(5)-substituent selected from the group consisting of -AL 1 -A, phenoxyphenyl, aryl, heteroaryl, aryl substituted heteroaryl, and heterocyclic; wherein AL 1 is an optionally substituted C 2-6 alkenylidene moiety, and A is an optionally substituted alicyclic, heteroalicyclic, aromatic or heteroaromatic moiety; R 1 is hydrogen, methyl, —C(═O)(CH 2 ) m R 1A , —C(═O)OR 1A , —C(═O)N(R 1A ) 2 or —SO 2 R 1A ; wherein m is an integer from 0-3; each occurrence of R 1A is independently hydrogen or an optionally substituted aliphatic, alicyclic, heteroaliphatic, heteroalicyclic, aromatic or heteroaromatic moiety; and R 2 is one or more substituents selected from the group consisting of hydrogen, halogen, hydroxyl, —NO 2 , —CN, arylcarbonylvinyl, S-heteroaryl, an optionally substituted aliphatic, heteroaliphatic, aromatic, heteroaromatic moiety; —CH 2 R a , —OR R , —S(═O) n R d , —NR b R c , and —C(═O)R a ; wherein n is 0-2, R R is an optionally substituted aliphatic, heteroaliphatic, aromatic or heteroaromatic moiety; R a , for each occurrence, is independently selected from the group consisting of hydrogen, hydroxy, aliphatic, heteroaliphatic, aryl and heteroaryl; R b and R c , for each occurrence, are independently selected from the group consisting of hydrogen; hydroxy; SO 2 R d ; aliphatic, heteroaliphatic, aryl and heteroaryl; R d , for each occurrence, is independently selected from the group consisting of hydrogen; —N(R e ) 2 ; aliphatic, aryl and heteroaryl; and R e , for each occurrence, is independently hydrogen or aliphatic.